


MK-0616

PCSK9

oral macrocyclic peptide inhibitor of PCSK9
Ph. III for hypercholesterolemia planned 2H 2023
from mRNA display + SBDD
J. Am. Coll. Cardiol., April 25, 2023


MERCK, RAHWAY, NJ



RMC-6291

KRAS^{G12C}

oral KRAS^{G12C}(ON) tri-complex inhibitor
Ph. I/II for adv. solid tumors
from FBDD + SBDD
AACR, April 2023
REVOLUTION MEDICINES, REDWOOD CITY, CA




camlipixant

P2X3

oral BID P2X3 receptor antagonist
Ph. III for first-line treatment of refractory chronic cough
non-competitive homotrimeric receptor antagonist; discovery not disclosed
GSK acquisition announcement, April 18, 2023


ASTRAZENECA/NEOMED/BELLUS HEALTH/GSK



BAY-747

sGC


oral QD sGC stimulator
Ph. I in healthy volunteers completed
from HTS + optimization
J. Med. Chem., April 11, 2023
BAYER, WUPPERTAL, DE



gepotidacin

bacterial topoisomerase


oral BID antibacterial Type II topoisomerase inhibitor
Ph. III for uncomplicated UTIs
from unbiased antibacterial screen + opt.
ECCMID, April 2023
GLAXO (GSK), STEVENAGE, UK



CFT1946

BRAFV600X


oral mutant-selective BRAFV600X degrader
Ph. I for BRAF-driven cancers
from CRBN-based E3 recruiter + vemurafenib
AACR, April 2023
C4 THERAPEUTICS, WATERTOWN, MA



IOA-244

PI3Kd


oral QD non-competitive PI3Kd inhibitor
Ph. I in metastatic cancers
from focused kinase inhibitor screen (60K cmpds) + opt.
Cancer Res. Commun., April 14, 2023
MERCK SERONO / IONCTURA, CH



ARV-766

AR


oral AR-degrading PROTAC
Ph. II for adv. prostate cancer
from CRBN-based E3 recruiter + AR ligand
AACR, April 2023
ARVINAS, NEW HAVEN, CT



difamilast

PDE4B

topical PDE4 inhibitor
marketed in Japan
PDE4B subtype-selective inhibitor; discovery not disclosed
JPET, April 11, 2023
OTSUKA, TOKYO, JP



navoximod

IDO

oral IDO1 inhibitor
Ph. I completed (50-800 mg) for cancer
from phenylimidazole + SBDD
JPET, April 14, 2023
NEWLINK / GENENTECH